Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712608 | 0.79 | MAPT (0.46) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1713071 | 0.77 | MAPT (0.43) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL16348106 | 0.76 | MAPT (0.42) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1712705 | 0.76 | MAPT (0.42) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2746473 | 0.76 | MAPT (0.42) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL12347996 | 0.74 | RIPK1 (0.49) | MAPTCNR1 | |
| SCHEMBL8434418 | 0.73 | MAPT (0.43) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL11282691 | 0.73 | MAPT (0.43) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5512327 | 0.72 | CHRNB2 (0.40) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL4977804 | 0.72 | MAPT (0.39) | MAPTCHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2684870-A1 | METHOD FOR PREPARING THIOCARBOXYLIC ACID S-(FLUOROALKYL) ESTER | Sumitomo Chemical Company Limited (JP) | 2014-01-15 | — | — | EP | disclosed |
| EP-2664613-A1 | Process for producing amide compounds | Sumitomo Chemical Company, Limited (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-2662355-A1 | Process for producing a (fluoroalkylthio) acetonitrile | Sumitomo Chemical Company, Limited (JP) | 2013-11-13 | — | — | EP | disclosed |
| EP-2465846-A1 | PROCESS FOR PREPARATION OF (FLUOROALKYLTHIO)ACETIC ACID ESTERS | Sumitomo Chemical Company, Limited (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-20120101294-A1 | PROCESS FOR PRODUCING (FLUOROALKYLTHIO) ACETIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101294-A1 | PROCESS FOR PRODUCING (FLUOROALKYLTHIO) ACETIC ACID ESTER | GRHPR, AKR7A2, FAR1 | MAPT 4195/4885CHRNB2 4208/4885CHRNB4 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.